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Introduction
The discovery of insulin by Banting and Best
in the early 1920’s was one of modern
medicine’s most important achievements. The
patients with diabetes due to an incapability
of their pancreatic beta-cells to produce insu-
lin, subsequently termed insulin-dependent
or type 1 diabetic patients, could be rescued
from otherwise inescapable death. However,
although exogenous insulin prevented acute
death from diabetic ketoacidosis, it was un-
able to fully normalize glucose metabolism,
thus leading to higher blood glucose levels in
insulin-treated diabetic patients than in
healthy subjects. Later, long-lasting diabetes
was found to be associated with secondary
complications involving the heart, blood ves-
sels, eyes, nerves, and the kidneys.
In 1936, Kimmelstiel and Wilson [1] de-
scribed the specific structural changes in dia-
betic kidney disease (diabetic nephropathy)
in combination with the clinical features of
elevated blood pressure, grossly enhanced ex-
cretion of protein in the urine, edema, and
renal failure. In addition, it became evident
that the condition was not solely a disease of
the kidneys but was associated also with se-
vere forms of retinal changes leading to vi-
sual impairment, with dysfunction of the ner-
vous system, and with a massively increased
risk for cardiovascular morbidity and early
death.
Epidemiological studies have demonstrated
that diabetic nephropathy occurs in approxi-
mately one-third to one half of all patients
with type 1 diabetes [2] and, today, diabetes
is the most important cause of renal failure in
the industrialized world [3, 4]. Although el-
evated blood glucose is of crucial importance
[5], it is not the only determinant of diabetic
nephropathy. Only a subgroup of patients
seems to be susceptible to this long-term com-
plication of diabetes, and, since the condition
has been found to cluster in families [6], the
development of diabetic nephropathy is likely
to be governed also by genetic factors.
In order to elucidate the nature of such ge-
netic determinants, the present studies were
undertaken to examine whether any associa-
tion exists between diabetic nephropathy and
the familial clustering of traits such as elevated
blood pressure, diabetes, and elevated excre-
tion of protein in the urine.
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History and classification of diabetes
A wonderful but not very frequent affection among
men, being a melting down of the flesh and limbs
into urine … life is short, offensive and distress-
ing, thirst unquenchable, death inevitable.
This description of the diabetic state by
Aretaeus of Cappadocia is approximately 2000
years old [7]. Although he was the first known
to use the term ‘diabetes’ (Greek: dia
[through] and bainein [go]), he had no knowl-
edge of the underlying abnormalities of the
disease. However, the typical symptoms and
findings of the diabetic patient, with sweet
urine, intense thirst, profuse urination, weight
loss, vomiting, drowsiness, coma, and death,
are described in the old Hindu literature prob-
ably originating from the period between
2500 and 600 BC [8]. In European medicine,
attention was drawn to the sweet taste of the
urine in some patients by Willis in England
in the 17th century [8], but it was not until
the work by Claude Bernard in the middle of
the 19th century that the basic principles of
glucose metabolism were understood [9].
Hindu medicine recognized two types of
diabetes, one affecting strong and corpulent
persons, the other weak and lean ones, and
stated that the two subtypes should be treated
differently [8]. Investigations in the era of
modern medicine confirmed this observation,
and in 1936, Himsworth proposed at least two
clinical types of diabetes, one insulin-sensi-
tive due to insulin deficiency, the other insu-
lin-insensitive [10]. Later, the terms ‘juvenile
onset’ and ‘maturity onset’ diabetes were
widely used, but the lack of a general consen-
sus regarding their definition caused confu-
sion. Therefore, at the end of the 1970s and
beginning of 1980s, two separate expert com-
mittees [11, 12] agreed on the classification
of diabetes into type 1 or insulin-dependent
diabetes mellitus and type 2 or non-insulin-
dependent diabetes mellitus in addition to a
spectrum of other types of diabetes. The di-
agnostic criteria for diabetes have recently
been revised [13, 14] as the knowledge of the
consequences of minor elevations of blood
glucose levels has increased.
The natural history of diabetic
nephropathy
Although proteinuria had long been recog-
nized as associated with diabetes, observations
by Kimmelstiel and Wilson in 1936 became
the foundation of the work leading to the cur-
rent understanding of diabetes-specific lesions
of the kidney, also called diabetic nephropa-
thy [1]; they described the specific renal his-
tology of diabetic nephropathy in association
with the clinical features of hypertension, al-
buminuria, edema, and renal failure in an
autopsy study on a series of eight patients of
whom seven had diabetes.
All patients with type 1 diabetes do not
develop nephropathy. According to epidemio-
logical studies performed to describe the natu-
ral history of the disease [2, 15], diabetic
nephropathy develops in slightly less than half
(35–45%) the patients during the 40 years
following diagnosis of diabetes. A striking
peak in annual incidence rate occurs after 10
to 20 years of diabetes, after which the risk
for nephropathy diminishes. Furthermore,
male gender increases risk.
The stages in development and progression
of diabetic nephropathy in type 1 diabetes are
Johan Fagerudd
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depicted in Table 1 (modified from Mogensen
[16]). The initial stage is characterized by re-
nal hyperfunction that is normalized by the
initiation of insulin therapy [17]. The kid-
ney structure is normal at the onset of diabe-
tes, but already during the first, clinically si-
lent phase of normoalbuminuria, renal struc-
tural changes become discernible [18, 19].
The first clinical sign of renal microvascular
complications is a slight increase in urinary
albumin excretion rate (UAER). This condi-
tion, referred to as microalbuminuria or in-
cipient diabetic nephropathy, is a powerful
predictor of subsequent overt nephropathy
[20–22], even though its predictive value
seems to be dependent on the duration of the
diabetes [23]. Blood pressure rises together
with the increase in albuminuria and is clearly
elevated early at the stage of overt diabetic
nephropathy [24, 25]. At the time proteinuria
develops, kidney function is usually normal,
but soon, glomerular filtration rate (GFR)
relentlessly deteriorates. The rate of decline
in GFR averages approximately 10 ml/min/
year, with a considerable interindividual vari-
ability [26, 27]. The process culminates in a
complete loss of kidney function.
Without intervention other than insulin,
the prognosis of diabetic nephropathy is poor.
Half the patients are dead within seven years
after the development of persistent proteinuria
[2], predominantly due to renal failure, but
also due to a massively increased risk for car-
diovascular death [2, 28, 29]. Life-expectancy
in type 1 diabetes is highly dependent on the
development of nephropathy. In comparison
to the background population, there is a two-
fold increase in relative mortality even in type
1 diabetic patients who do not develop pro-
teinuria. However, in type 1 diabetic patients
with nephropathy, relative mortality is ex-
tremely high, increasing to a maximum of
100-fold at age 35 [30]. In addition, quality
of life is severely impaired in patients with
nephropathy due to the clustering of other
micro- and macrovascular complications [28,
31–34].
The changing natural history
of diabetic nephropathy
The natural history of diabetic nephropathy
has changed dramatically through progress in
the care of diabetic patients during recent
decades. Intensified insulin therapy has a ben-
eficial effect on development of diabetic renal
complications. Shortly after onset of diabe-
tes, initiation of insulin pump therapy nor-
malizes the initial glomerular hyperfiltration
[35, 36]. Later, as demonstrated in The Dia-
betes Control and Complications Trial, inten-
sified insulin therapy, achieved either by in-
sulin pump treatment or multiple insulin in-
jections, resulting in a lowering of mean
glycosylated hemoglobin A
1c
 (HbA
1c
) from
9% to 7% over six years, diminishes risk for
microalbuminuria by 39% and that for albu-
minuria by 54% [5]. Furthermore, improve-
Stage
I. Acute hypertrophy-
hyperfunction
II. Normoalbuminuria
III. Microalbuminuria
(incipient diabetic nephropathy)
IV. Proteinuria
(overt diabetic nephropathy)
V. End stage renal disease
Table 1. Stages in the development of diabetic nephropathy in type 1 diabetes
Chronology
At diagnosis
1–5 years
6–15 years
15–25 years
Over 25 years
UAER
Normala
Normal
(<20 µg/min)
↑
(20–200 µg/min)
↑↑↑
(>200 µg/min)
Not measurable
Kidney structure
Kidney size ↑
glomerular size ↑
GBM thickness ↑
mesangial expansion ↑
GBM thickness ↑↑
mesangial expansion ↑↑
Pronounced
abnormalities
Advanced abnormalities
Blood
pressure
Normalb
Normalb
↑
↑↑↑
↑↑↑
aMay be transiently elevated. bAs in the background population.
GFR
↑↑
↑↑
↑↑
↑–↓↓
↓↓↓
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ment in glycemic control (change in HbA
1c
from 10% to 8.5%) by means of continuous
subcutaneous insulin infusion retards the pro-
gression of morphological renal changes [37].
Whether intensified insulin therapy has a
similar beneficial effect on the rate of decline
in GFR is unclear [38–40], although such an
effect was demonstrated in a study including
patients with microalbuminuria at baseline
[40]. Thus, intensive glycemic control has
great potential, especially in the primary pre-
vention of diabetic nephropathy, and should
always be an aim.
Effective antihypertensive treatment reduces
the rate of decline of GFR [41–43]. Inhibi-
tors of the angiotensin-converting enzyme
(ACE) have been proposed to have a specific
renal protective effect beyond their blood pres-
sure-lowering ability in patients with overt
nephropathy [44, 45], although recent evi-
dence suggests that other agents, for instance
calcium-channel blockers, may be equally ca-
pable of preserving kidney function [46].
However, in the primary prevention of dia-
betic nephropathy, ACE inhibitors are indis-
putably efficient [47–50] and may also pre-
vent progression of diabetic retinopathy [51].
Prior to the 1970´s, renal replacement therapy
was generally not offered to a patient with
uremia which was due to diabetic nephropa-
thy, since the prognosis was considered as too
poor [4, 52]. Today, diabetes is the most com-
mon reason for actively treated uremia in the
Western world [3, 4]. Renal-transplant recipi-
ents seem to have a favourable prognosis com-
pared to patients treated with dialysis [53],
and promising results have emerged from
combined pancreas–kidney transplantation
[54].
These improvements in the care of the dia-
betic patient have indeed had an impact on
prognosis. In one cohort with excellent gly-
cemic control, a pronounced decrease has
occured in the cumulative incidence of neph-
ropathy [55]. Furthermore, recent evidence
suggests that median survival time from on-
set of proteinuria has doubled to 14 years [2,
56], most likely an effect of intensified anti-
hypertensive treatment (Figure 1). Finally,
according to the Finnish Registry for Kidney
Diseases, median survival time in type 1 dia-
betic patients with diabetic nephropathy who
developed end-stage renal disease (ESRD) in
the time period 1985–1998, was approxi-
mately 5.5 years from onset of uremia [4]. In
other words, the prognosis of a patient with
ESRD today is quite similar to that of a pa-
tient with the first sign of diabetic renal dis-
ease – dipstick-positive proteinuria – two or
three decades ago. However, despite these re-
cent improvements, diabetic nephropathy is
still an important cause of increased morbid-
ity and premature death among patients with
diabetes, and constitutes a heavy and grow-
ing burden on the health care systems
throughout the world.
Renal structural changes
in diabetic nephropathy
Kimmelstiel and Wilson, the first investiga-
tors to describe the characteristic “intercapil-
lary”, nodular thickening of the mesangium,
related these findings to the clinical syndrome
100
80
60
40
20
0
Cumulative death rate (%)
Duration of nephropathy (years)
0 4 8 12 16
Before 1953
1970’s and 1980’s
Figure 1.  Cumulative death rate after onset of diabetic
nephropathy in patients diagnosed with diabetes before
1953 according to Andersen et al [2] and in patients
diagnosed with diabetes mainly in 1970s and 1980s
according to Rossing et al [56]. The prognosis of
diabetic nephropathy has improved (median survival
7 vs 14 years after onset of proteinuria).
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of diabetic nephropathy [1]. Characteristics
of the glomerular and interstitial lesions in
advanced diabetic nephropathy are listed in
Table 2.
Structural changes in relation to albuminuria
As a group, type 1 diabetic patients with long-
duration diabetes and a UAER within the
range of normoalbuminuria display mild
structural lesions in their kidneys, such as
thickening of the glomerular basement mem-
brane (GBM) and mesangial expansion [57].
There is, however, within the group a consid-
erable overlap, with kidney structure rang-
ing from normal to rather advanced lesions
[57]. At the stage of microalbuminuria, there
is a further thickening of the GBM, together
with more pronounced expansion of the
mesangium [57–60]. In overt nephropathy,
these structural changes become more ad-
vanced, although a considerable heterogene-
ity exists in lesions between patients and even
from one glomerulus to another within the
same patient [59].
As can be expected, UAER correlates with
a variety of glomerular lesions such as GBM
thickening and degree of mesangial expan-
sion [58]. However, in one follow-up study
with two kidney biopsies performed at a five-
year interval in type 1 diabetic patients with
UAER varying from normo- to macroalbu-
minuria, the structural variable most consis-
tently correlating with increase in UAER was
the mesangial volume fraction [61].
Structural changes in relation to kidney function
Even the initial glomerular hyperfiltration,
early in the course of type 1 diabetes, is asso-
ciated with structural changes in the kidney
such as increase in kidney size [17] and in the
size of the glomeruli [62]. The glomerular
filtration surface area, i.e., the part of the cap-
illary wall that is directed towards the uri-
nary space and is not in contact with the
mesangium, is similarly increased [63]. In
overt diabetic nephropathy, decline in GFR
correlates strongly with the decreasing glom-
erular filtration surface area [64, 65]. Late
stages of diabetic nephropathy are character-
ized by a high percentage of occluded glom-
eruli in combination with compensatory hy-
pertrophy and increased filtration surface area
in the non-occluded glomeruli [66].
Pathogenesis of diabetic nephropathy
Hyperglycemia
Hyperglycemia is the key player in the devel-
opment of diabetic nephropathy. The charac-
teristic structural lesions of diabetic nephr-
opathy are absent at the onset of type 1 dia-
betes. However, after two years of diabetes,
GBM thickening and mesangial expansion are
already distinguishable, and at five years, these
changes are advanced [18, 19]. Furthermore,
when normal kidneys are transplanted into a
diabetic milieu, lesions typical of diabetic
nephropathy develop [67–71]. In type 1 dia-
betic patients with microalbuminuria, im-
proved glycemic control by means of intensi-
fied insulin therapy retards the progression
of morphological changes [37]. Furthermore,
as demonstrated in a group of type 1 diabetic
patients with mild to advanced glomerular
lesions at the time of pancreas transplanta-
tion, ten years of normoglycemia has induced
reversal of renal structural lesions [72]. Fi-
Table 2. Structural lesions in diabetic nephropathy
(adapted from Mauer et al [244])
GBM thickeninga
Mesangial expansion (diffuse glomerulosclerosis)a
Intense immunofluorescence staining for albumin in
GBM, tubular basement membrane and Bowman’s
capsulea
Kimmelstiel-Wilson nodules (nodular
glomerulosclerosis)b
Afferent and efferent glomerular arteriolar hyalinizationb
Tubular basement membrane thickening
Subendothelial hyaline exudative lesions (fibrinoid cap)
Parietal Bowman’s capsular surface “capsular drop”b
aAlways present. bIf present, highly characteristic of
diabetic nephropathy.
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nally, intervention studies have demonstrated
in diabetic patients with intensive glycemic
control a decreased risk for progression of
UAER [5, 73].
Which are the biochemical mechanisms re-
sponsible for the harmful effects of high blood
glucose on the kidney? Chronic exposure to
hyperglycemia causes formation of advanced
glycosylation end-products (AGEs) via non-en-
zymatic glycosylation of extracellular macro-
molecules [74]. AGEs are formed from early
glycosylation products in a chemical reaction
that is irreversible. Tissue accumulation of
AGEs is associated with cross-linking of long-
lived extracellular proteins and induces ab-
normalities in critical matrix protein functions
such as basement membrane self-assembly and
the binding of heparan sulfate proteoglycan.
AGEs also induce increased formation of ex-
tracellular matrix via stimulation of produc-
tion of growth-promoting cytokines [74].
High levels of AGEs have been found circu-
lating in the serum and are found incorpo-
rated into the arterial walls of diabetic pa-
tients who have nephropathy [75]. Further-
more, administration of advanced glycosylated
albumin to non-diabetic rats induces pro-
teinuria and morphological changes similar
to those seen in diabetic nephropathy [76].
The important role of AGEs in development
of diabetic nephropathy is highlighted when
administration to diabetic rats of aminogua-
nidine, an inhibitor of formation of AGEs,
prevents the expected rise in albuminuria
[77].
Through the polyol pathway, glucose is
transformed into sorbitol, a reaction in which
aldose reductase is the rate-limiting enzyme.
When sorbitol and other polyols accumulate
intracellularly, disturbances in the cellular
osmoregulation and a decrease in the intrac-
ellular myoinositol follow, with tissue dam-
age as the consequence [78]. After treatment
of diabetic rats with an aldose reductase in-
hibitor, diminished proteinuria was evident
[79, 80]. Unfortunately, findings in human
beings have been conflicting [81, 82].
The protein kinase C (PKC) family includes
at least eleven isoenzymes that act as intrac-
ellular serine/threonine kinases and are in-
volved in various cellular signal transductions.
Glucose-induced activation of PKC is associ-
ated with increased permeability, increased
production of cytokines and of extracellular
matrix, with cell proliferation, and with an-
giogenesis in vascular cells [83]. A specific
inhibitor of the PKC-β isoform has been
shown in diabetic rats to normalize glomeru-
lar hyperfiltration and decrease UAER [84].
Abnormalities in extracellular matrix
In the healthy glomerulus, the barrier between
the capillary and the urinary space can be
thought of as a membrane perforated by pores
and coated with an inner layer of negatively
charged molecules, mainly heparan sulfate
proteoglycan and sialic acid [85]. The trans-
glomerular passage is therefore dependent on
both the size and the charge of a molecule in
addition to hemodynamic forces. The heparan
sulfate proteoglycan content is decreased in
the capillary wall of type 1 diabetic patients
with nephropathy [86]. In addition, the
undersulfation of heparan sulfate molecules
demonstrated in experimental diabetes [87],
results in a further reduction in the anionic
sites of the GBM. One consequence is an in-
creased ability of the negatively charged al-
bumin to pass through the glomerular filter.
Since this increased permeability is not lim-
ited to the glomerulus but is present through-
out the vascular bed, a decrease in the anionic
content of the lining of the endothelium has
been proposed as a common denominator for
the deleterious triumvirate of long-term dia-
betic complications: nephropathy, retinopa-
thy, and macrovascular disease [88]. Interest-
ingly, treatment of patients with type 1 dia-
betes with low molecular weight heparins,
assumed to restore the heparan sulfate
proteoglycan content, has been found to re-
duce albuminuria [89] and to improve reti-
nal hard exudates [90]. Abnormalities in the
extracellular matrix may thus be important
in the cascade leading in diabetes both to
nephropathy and to associated micro- and
macrovascular complications.
Johan Fagerudd
14
Review of the literature
Hemodynamic factors
Autopsy findings in a patient with long-
standing diabetes and unilateral renal artery
stenosis revealed only mild ischemic changes
on the stenotic side, whereas advanced dia-
betic nephropathy was evident on the con-
tralateral side exposed to both hyperglycemia
and hypertension [91]. Surgical induction of
unilateral renal artery stenosis in rats has
shown a similar effect [92]. Hemodynamic
factors thus seem to influence the develop-
ment of diabetic nephropathy. As put forward
by Hostetter, Rennke, and Brenner [93],
intraglomerular hypertension and single-
nephron hyperfiltration induced by the dia-
betic state may lead to increased transglom-
erular passage of proteins, resulting in their
accumulation in the mesangium. This may
act as a stimulus for proliferation of mesangial
cells, leading to sclerosis of the glomeruli.
Compensatory hyperfiltration in the surviv-
ing glomeruli then completes the vicious cycle
and induces progressive loss of renal function.
This hypothesis gains support from several
observations. Glomerular hyperfiltration is
frequently present in both type 1 and type 2
diabetes, in particular during poor metabolic
control [17, 94]. Patients who later develop
microalbuminuria or proteinuria have shown
a higher GFR early in the course of their dia-
betes [95]. In an 8-year follow-up study in
patients with type 1 diabetes [96], initial
hyperfiltration predicted development of mi-
cro- or macroalbuminuria, although another
study found the role of early hyperfiltration
to be less pronounced [97]. Furthermore, re-
duction in number of nephrons is associated
with a reduced filtration surface area and
single nephron glomerular hyperfiltration
[98]. Indeed, several conditions associated
with a reduced number of nephrons, such as
low birth weight [99, 100] and short stature
[101] and also loss of one kidney [102, 103],
have been linked in diabetes to an increased
risk of elevated UAER. Hemodynamic fac-
tors thus seem to play an important role in
the development and progression of diabetic
glomerulopathy.
The issue as to whether the rise in sys-
temic blood pressure usual in diabetic neph-
ropathy precedes or follows the rise in UAER,
has been subject to debate [104–106]. How-
ever, results from a longitudinal study ap-
plying 24 h ambulatory blood pressure moni-
toring (24 h ABPM) indicate a parallel rise
in UAER and in systemic blood pressure in
the transition from normo- to microalbumin-
uria [24]. In that study, base-line systemic
blood pressure did not differ between
progressors and non-progressors, but the rise
in progressors’ UAER was closely correlated
with their rise in 24 h ambulatory blood pres-
sure during follow-up.
Growth factors
The term ‘growth factor’ is used for any sub-
stance capable of inducing cellular differen-
tiation or proliferation and embraces an in-
creasing number of peptides. In the initiation
and progression of diabetic nephropathy,
growth factors such as growth hormone, in-
sulin-like growth factor, epidermal growth
factor, transforming growth factor, platelet-
derived growth factor, tumor necrosis factor-
α, and fibroblastic growth factors have all been
suggested to play a role [107]. Of these, trans-
forming growth factor-β (TGF-β) is of par-
ticular interest due to its wide effects on ex-
tracellular matrix [108]. In the normal situa-
tion, TGF-β induces deposition of extracel-
lular matrix after tissue injury. However, in
the diabetic state, a sustained secretion of
TGF-β resulting in an inappropriate produc-
tion of collagen IV, fibronectin, and proteo-
glycans among others, may be caused by sev-
eral stimuli. First, high glucose concentration
induces messenger RNA expression of TGF-
β in glomerular cells [109] and the increased
production of collagen by mesangial cells ex-
posed to high glucose is at least in part medi-
ated by TGF-β [110]. Second, activation of
the renin-angiotensin system with enhanced
formation of angiotensin II may influence
extracellular matrix protein synthesis through
TGF-β [111]. Third, AGEs stimulate collagen
production by mesangial cells via pathways
15
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that involve TGF-β [112]. The importance
of TGF-β is further underlined by the dem-
onstration of a rapid development of glom-
erulosclerosis after in vivo transfection of the
TGF-β1 gene into the kidneys of non-diabetic
rats [113].
Genetic factors
Renal disease, regardless of underlying cause,
has been found to aggregate in families [114,
115]. In addition, substantial racial differences
exist in the occurrence of diabetic nephropa-
thy – for instance, non-Ashkenazi Jewish type
1 diabetic patients are at higher risk than are
Ashkenazi patients [116]; moreover, Pima
Indian, African-American, and Mexican-
American type 2 diabetic patients have a
higher risk than do Caucasian patients [117–
119]. A genetic predisposition both to dia-
betic and non-diabetic nephropathy thus
seems likely.
Seaquist et al [6] were the first to describe
a familial aggregation of albuminuria in type 1
diabetes. Elevated UAER was found among
83% of diabetic siblings of patients with
nephropathy, but in only 17% of the siblings
of patients without nephropathy. Three sub-
sequent studies [120–122] confirmed this
finding, although their degree of familial clus-
tering was less pronounced. A recent study of
mainly normoalbuminuric type 1 diabetic sib-
ling pairs demonstrated a familial effect not
only on UAER, but also on the severity and
pattern of glomerular structural lesions [123].
Familial aggregation of nephropathy has also
been demonstrated in type 2 diabetes [124–
127]. Interestingly, minor abnormalities in
UAER seem to be present in individuals with
a potential genetic susceptibility to diabetic
nephropathy even in the absence of diabetes.
This suggestion is based on the finding of an
elevated UAER in ordinary urine collections
[126, 128–130] as well as of an exaggerated
albuminuric response to physical exercise
[129] in non-diabetic offspring and siblings
of type 2 diabetic patients with micro- or mac-
roalbuminuria. Whether similar abnormali-
ties in UAER are present also in the non-dia-
betic relatives of type 1 diabetic patients with
nephropathy remains unknown.
Susceptibility to diabetic nephropathy may
be linked to familial predisposition to hyperten-
sion, since parents of type 1 diabetic patients
with proteinuria have been found to have
higher arterial blood pressure than do parents
of non-proteinuric patients, a finding origi-
nally described by Viberti and co-workers
[131]. Although some subsequent studies
have confirmed this finding, others have
yielded conflicting results [132–137, 201],
making the role of familial predisposition to
essential hypertension in development of dia-
betic nephropathy in type 1 diabetes still
unclear.
Furthermore, activity of the sodium–
lithium countertransporter in red blood cells,
a potential indicator of a genetic predisposi-
tion to hypertension [139, 140], has been
found to be increased in type 1 diabetic pa-
tients with nephropathy [132, 141] and in
their parents [135]. Abnormalities have also
been reported in the closely related sodium–
hydrogen countertransporter [142]. However,
conflicting results have also appeared [134]
and the exact role of these phenotypic mark-
ers of essential hypertension in the develop-
ment of diabetic nephropathy remains to be
established.
Earle and co-workers [136] demonstrated
that a parental history of cardiovascular disease
was associated with increased risk for diabetic
nephropathy. A Danish case-control study
[143] did not, however, find any difference
in prevalence of cardiovascular disease be-
tween parents of patients with and without
nephropathy. The prevalence of cardiovascu-
lar disease was much lower in the latter study,
probably due to lower age (parental mean age
58 vs 64), which could explain some of the
differences between the two studies.
In non-diabetic subjects with a family his-
tory of diabetes, a spectrum of metabolic de-
rangements such as insulin resistance, ab-
dominal obesity, elevated blood pressure, and
lipid abnormalities has been described [144,
145]. Interestingly, similar metabolic and
hemodynamic derangements are also found at
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the early stages of diabetic nephropathy [26,
146–151]. It could therefore be hypothesized
that a family history of diabetes increases the
risk for diabetic nephropathy, and indeed, in
the Pima Indians, a link was demonstrated
between familial diabetes and diabetic neph-
ropathy [152]. Whether a family history of
diabetes increases the risk for nephropathy in
type 1 diabetes is unknown. However, family
members of patients with microalbuminuria
have shown metabolic derangements such as
hyperinsulinemia, elevated cholesterol and
apolipoprotein B levels, and an increased LDL/
HDL cholesterol ratio [153].
Genetics
Because the evidence for genetic factors in the
development of diabetic nephropathy is con-
vincing, efforts have been made to identify
one or several genes increasing susceptibility
to diabetic nephropathy. Recent results from
segregation analyses in pedigrees of type 2
diabetic patients speak in favor of a major gene
effect in the development of albuminuria [154,
155]. Similar analyses are very difficult to
perform in type 1 diabetes due to the scarcity
of large pedigrees with many affected indi-
viduals. However, in the study on type 1 dia-
betic sibling pairs by Quinn et al [121], the
cumulative incidence rate for diabetic nephr-
opathy after 25 years of diabetes was much
higher in siblings of patients with nephropa-
thy than in siblings of patients without neph-
ropathy, 71% vs 25%, respectively. This find-
ing has been interpreted as indicative of a
major gene effect on diabetic nephropathy also
in type 1 diabetes. Therefore, in the light of
present understanding, diabetic nephropathy
seems to be the result of one or several major
or minor genes in combination with environ-
mental factors, of which the most important
is hyperglycemia [156].
Table 3 presents some of the genes sug-
gested to be involved in the development of
diabetic nephropathy. Thus far, the study de-
sign most widely used to identify such genes
has been the candidate gene approach in case-
control study settings. As an example, the
candidate gene most thoroughly studied has
been the insertion(I)/deletion(D) polymor-
phism in the ACE gene. This polymorphism
is especially attractive, since it accounts for
half of the variance in serum ACE level [157].
Numerous studies have addressed the issue of
a role for the ACE I/D-polymorphism in the
development of diabetic nephropathy with di-
verging results [158]. Some evidence suggests
that the D-allele may increase the risk for dia-
betic nephropathy in Japanese type 2 diabetic
patients, while the effect in Caucasian type 1
diabetic patients, if present at all, seems to be
only minor [158, 159]. However, it should
be noted that case-control studies are espe-
cially prone to biases such as selective survival
and population stratification. At present, none
of the candidate genes in Table 3 qualifies as
a gene with a major impact on the develop-
ment of diabetic nephropathy.
Linkage analysis in type 1 diabetic sibling
pairs discordant for diabetic nephropathy has
identified a region on chromosome 3 in link-
age with diabetic nephropathy [160]. The
most obvious candidate gene in this region is
the angiotensin II type 1 receptor gene, but
subsequent analysis has found no evidence of
DNA sequence differences in this gene with
any impact on the development of nephropa-
thy. However, this region may harbor a yet-
unidentified gene with a major effect on de-
velopment of diabetic nephropathy.
Other factors
Restriction of dietary protein intake retards in
animal models the progression of renal dis-
ease [161]. Suggested mediators of this ben-
eficial effect include a reduction in glomeru-
lar hyperfiltration/hypertension, a preserva-
tion of proper glomerular permeability, and
actions mediated via lipid metabolism. In
humans, dietary protein restriction has been
thoroughly studied in non-diabetic kidney
diseases, and, according to a meta-analysis
[162], a low protein diet has a beneficial ef-
fect on the rate of loss of kidney function. In
diabetic nephropathy, the studies conducted
thus far have been small, and in some cases,
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uncontrolled [163–167], and although the
combined results indicate that protein restric-
tion slows the progression of diabetic nephr-
opathy [162], larger studies are needed to
define the role of protein restriction in dia-
betic renal disease.
Type 1 diabetic patients with diabetic
nephropathy display abnormalities of lipid me-
tabolism including slightly elevated levels of
total and LDL cholesterol, triglycerides, and
apolipoprotein B [148, 168]. Such an athero-
genic profile may contribute to the massively
increased risk for cardiovascular complications
in patients with nephropathy [30]. In type 2
diabetes, high cholesterol levels increase the
risk for development of elevated UAER [169].
In type 1 diabetes, multiple abnormalities of
lipid metabolism are already evident at the
microalbuminuria stage [148, 168], but little
information exists on the role of lipid abnor-
malities in the progression from normal to
elevated UAER. In overt nephropathy, hyper-
cholesterolemia has been associated with an
accelerated decline in renal function [170–
172] and with cardiovascular death [170].
However, although a recent animal study re-
ported positive effects on renal function of
lipid-lowering therapy with lovastatin [173],
treatment with statins in hypercholester-
olemic patients with elevated UAER failed
to show any benefit regarding progression of
UAER or rate of decline of GFR [174]. How-
ever, no data are available from long-term,
prospective, randomised trials.
Among other factors, smoking has been
found to increase the risk for development and
progression of diabetic nephropathy [175–
177] and thereby constitutes an important
modifiable risk factor in diabetic nephropa-
thy.
In addition, some evidence suggests a ben-
eficial effect of the c-peptide molecule on kid-
ney function in type 1 diabetes [178], and
patients with persisting c-peptide secretion
due to only partial destruction of pancreatic
β-cells may be protected against diabetic mi-
crovascular late complications [179].
Table 3. Examples of candidate genes for diabetic nephropathy
Mechanism
1. Renin angiotensin system
2. Blood pressure regulation, cardiovascular disease
3. Other
Candidate gene
Angiotensin converting enzyme
Angiotensinogen
Angiotensin II type 1 receptor
Kallikrein
α-adducin
Apolipoprotein E
Nitric oxide synthase (eNOS)
Glycogen synthase
Aldose reductase
Transforming growth factor-β
Heparan sulphate proteoglycan (Perlecan gene)
Methylenetetrahydrofolate reductase
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Aims of the study
One-third of all patients with type 1 diabetes
develop diabetic nephropathy. In addition to
being the most important cause of chronic
renal failure in the industrialized world, dia-
betic nephropathy is also associated with a
massively increased risk for cardiovascular
complications. At present, growing evidence
exists of a role for genetic factors in the de-
velopment of diabetic nephropathy. Identifi-
cation of such predisposing factors would al-
low targeting of high-risk individuals and a
possibility for intervention even at diagnosis
of diabetes. Little is known, however, about
the nature of the genetic factors increasing
the risk for nephropathy. The main objectives
of the present study were therefore to answer
the following questions:
1. Is diabetic nephropathy in type 1 diabe-
tes associated with familial predisposition
to hypertension? (I)
2. Is diabetic nephropathy in type 1 diabe-
tes associated with familial predisposition
to diabetes? (II)
3. If so, which abnormalities in glucose me-
tabolism are responsible for the excess
prevalence of diabetes seen in relatives of
type 1 diabetic patients with diabetic
nephropathy? (III)
4. Are abnormalities in UAER present in
non-diabetic first-degree relatives of type
1 diabetic patients with diabetic nephr-
opathy? (IV, V)
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All studies were cross-sectional case-control stud-
ies. Characteristics of the type 1 diabetic pa-
tients are depicted in Tables 4 and 5. The stud-
ies were conducted in accordance with the
Declaration of Helsinki [180], and the study
protocols were approved by the local ethics
committee. All patients and relatives gave
their written informed consent prior to their
participation.
A total of 318 Caucasian type 1 diabetic
patients took part. Type 1 diabetes was de-
fined as onset of diabetes before the age of 35,
initiation of insulin therapy within a year af-
ter diagnosis, and present treatment with at
least two daily insulin injections without the
use of any other antidiabetic drug. The sub-
jects were recruited from a random sample of
all patients with diabetic nephropathy attend-
ing the renal outpatient clinic or the dialysis
unit of the Helsinki University Central Hos-
pital between November, 1995, and Decem-
ber, 1997 (n = 137), and from a consecutive
sample of all patients attending the diabetic
outpatient clinic of the same hospital from
September, 1990, to February, 1992 (n = 73),
and via an advertisement in the newsletter of
the Helsinki Diabetes Association (n = 20).
Consequently, a total number of 174 patients
with signs of diabetic nephropathy and 56 pa-
tients with normal UAER were studied in
Helsinki. In addition, 88 Danish patients at-
tending the outpatient clinic at the Steno Dia-
betes Center, Gentofte, Denmark, participated
in Study I. Of these, 44 patients were ran-
domly selected from among all type 1 diabetic
patients with diabetic nephropathy who had
their GFR measured in 1993, together with
44 patients from an age-, duration- and sex-
matched control group with normal UAER.
Study design and subjects
Familial predisposition
to hypertension (I)
Study aim. To evaluate whether diabetic neph-
ropathy is associated with a familial predis-
position to hypertension.
Subjects. The parents (n = 109) of 73 patients
with overt diabetic nephropathy and those (n
= 112) of 73 patients with normal UAER and
a duration of diabetes exceeding 15 years
(Tables 4 and 5). In each group, 44 of the pa-
tients were recruited from the Steno Diabetes
Center in Gentofte, Denmark, while the rest
came from the outpatient clinics of the
Helsinki University Central Hospital.
Study design. Any antihypertensive medica-
tion taken by the parents was recorded, and
blood pressure was measured auscultatorily
in all parents not on antihypertensive medi-
cation (n = 162). Furthermore, 131 of the
162 parents taking no antihypertensive
medication volunteered for a 24 h ABPM.
The prevalence and cumulative incidence
of hypertension in the two groups of par-
ents were calculated after exclusion of those
parents with clear evidence of hypertension
secondary to renal disease. The impact of
parental hypertension on the development
of hypertension in the diabetic offspring was
also assessed.
Familial predisposition
to diabetes (II)
Study aim. To elucidate whether diabetic neph-
ropathy is associated with a familial predis-
position to type 2 diabetes.
Johan Fagerudd
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Study design and subjects
Subjects. Parents of 137 patients with overt
diabetic nephropathy and of 54 patients with
normal UAER (Tables 4 and 5) recruited from
the outpatient clinics of the Helsinki Uni-
versity Central Hospital and via the Helsinki
Diabetes Association.
Study design. Prevalence of known diabetes and
hypertension as well as overall and cardiovas-
cular death rate in the parents were assessed
in the two groups of patients. Furthermore,
an oral glucose tolerance test (OGTT) and
anthropometric measurements were carried
out in 95 and 55 living, non-diabetic parents
of patients with and without diabetic nephr-
opathy, respectively.
Familial abnormalities in
glucose metabolism (III)
Study aim. In order to explore the mechanisms
behind a possible association between diabetic
nephropathy and familial type 2 diabetes, glu-
cose metabolism was assessed in first-degree
relatives of type 1 diabetic patients with and
without elevated UAER.
Subjects. First-degree relatives (n = 114) of 43
patients with elevated UAER (microalbumin-
uria, n = 18; overt diabetic nephropathy, n =
25), and 93 relatives of 39 patients with nor-
mal UAER. The patients were recruited from
the outpatient clinics of the Helsinki Uni-
versity Central Hospital and via the Helsinki
Diabetes Association.
Study design. After exclusion of relatives with
treatment for diabetes or with fasting hyper-
glycemia, an OGTT was performed on all rela-
tives, with measurement of plasma glucose
and serum insulin responses. On a second oc-
casion, insulin sensitivity was measured by
the short insulin tolerance test (ITT) in 106
(89%) and 84 (89%) relatives of patients with
and without elevated UAER.
Familial abnormalities in urinary
albumin excretion rate (IV–V)
Study aim. Non-diabetic relatives of type 2
diabetic patients with elevated UAER have
been found to display abnormalities in UAER.
The aim was to discover whether this was also
Table 4. Characteristics of the type 1 diabetic patients
Patients
with
DN+
DN–
DN+
DN–
DN+
DN–
DN+
DN–
DN+
DN–
Study
I
II
III
IV
V
n
73
73
137
54
43
39
80
25
21
24
Sex
(M/F)
39/34
36/37
87/50*
25/29
22/21
18/21
52/28**
8/17
16/5
10/14
Age
(years)
37±1
37±1
42±1
42±1
37±1
40±1
41±1
41±2
40±2
41±2
Duration
(years)
25±1
25±1
30±1
28±1
25±1
26±1
30±1
27±2
29±2
29±2
HbA1c
(%)
9.4±0.2***
8.3±0.1
8.9±0.1***
8.1±0.1
9.1±0.2**
8.2±0.1
8.8±0.2*
8.1±0.2
9.0±0.3**
8.1±0.1
ESRD
(%)
10
–
43
–
21
–
51
–
38
–
UAER
(µg/min)
758 (48–8824)a
8 (1–19)
512 (19–8936)a
4 (1–19)
124 (9–3386)a
5 (1–19)
928 (70–8936)a
4 (1–11)
997 (191–8936)a
4 (1–19)
aIncludes patients with present UAER less than the cut-off levels for elevated UAER, but with previously documented
persistent micro- or macroalbuminuria. *P < 0.05, **P < 0.01 and ***P < 0.001 in comparison of patients with DN+ and
DN– within the different studies (significance of differences in prevalence of ESRD and in UAER not assessed).
Serum creatinine
(µmol/l)
94 (57–1141)***
78 (53–111)
173 (68–1176)***
83 (57–111)
92 (62–1176)**
85 (65–111)
177 (68–1176)***
78 (57–101)
152 (58–848)***
82 (57–108)
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Table 5. Characteristics of the relatives
Relatives of
patients with
DN+
DN–
DN+
DN–
DN+
DN–
DN+
DN–
DN+
DN–
Study
I
II
III
IV
V
n
109
112
95
55
114
93
186
52
21
24
Parents/
siblings
109/–
112/–
95/–
55/–
56/58
44/49
77/109*
30/22
–/21
–/24
Sex
(M/F)
42/67
42/70
36/59
22/33
49/65
43/50
85/101
22/30
12/9
14/10
Age
(years)
66±1
68±1
65±1
65±1
51±1
53±2
52±1
54±2
43±2
43±2
BMI
(kg/m2)
27.1±0.5*
25.9±0.3
28.2±0.4
27.2±0.6
26.1±0.4*
25.0±0.4
26.4±0.3
26.0±0.6
25.1±0.6
24.5±0.6
Smokers
(%)
47
36
19
24
25
30
27
25
43
33
*P<0.05 in comparison of relatives of patients with DN+ and DN– within the studies.
the case in non-diabetic relatives of type 1
diabetic patients with diabetic nephropathy.
Subjects. In Study IV, UAER was measured in
186 first-degree relatives of 80 patients with
overt diabetic nephropathy and in 52 relatives
of 25 patients with normal UAER (Tables 4
and 5). In Study V, basal and exercise-induced
UAER was measured in three urine collec-
tions from 21 and 24 age-, sex- and body mass
index (BMI)-matched siblings of patients with
and without diabetic nephropathy, respec-
tively. These patients were recruited from the
outpatient clinics of the Helsinki University
Central Hospital and via the Helsinki Diabe-
tes Association.
Study design. In Study IV, UAER was mea-
sured in one overnight urine collection from
relatives, in whom diabetes was excluded by
medical history. In Study V, an OGTT was
performed to exclude abnormalities in glu-
cose metabolism. UAER was measured from
urine collections which the relatives per-
formed overnight, during the OGTT, and
during a submaximal bicycle ergometer test.
Johan Fagerudd
22
Assessment of medical history
A careful medical history regarding the pres-
ence of hypertension, diabetes, cardiovascu-
lar disease, smoking habits and regular medi-
cation was taken from all participating rela-
tives in Studies I to V by use of a standard-
ized questionnaire. Hypertension was consid-
ered present if the subject was on medication
prescribed for elevated blood pressure. Dia-
betes was defined as a diagnosis of diabetes
made by a physician. Diabetes in the relatives
was classified as type 1 diabetes if age at on-
set of the disease was less than or equal to 40
years, and since diagnosis it had been treated
with no other antidiabetic drug than insulin.
All other cases of diabetes were classified as
type 2 diabetes. A history of cardiovascular
disease was defined as a history of acute myo-
cardial infarction or stroke. In cases with in-
complete information, medical records were
reviewed.
In Studies II and III, the participating type 1
diabetic patients were all interviewed with a
standardized questionnaire regarding the health
status of their first-degree relatives. The ques-
tionnaire assessed whether the relatives were
alive, the age of the relatives at the time of the
study and presence of diabetes or antihyperten-
sive treatment in the relatives. If a relative was
deceased, cause of death and age at death were
requested. Parental cardiovascular death was
considered to have taken place if the proband
reported death from cardiac causes, stroke, or
rupture of an aortic aneurysm. In Study II, the
reliability of the information obtained from the
patients was tested by interviewing living par-
ents and by reviewing medical records and death
certificates in those deceased. Confirmation of
data was carried out for all parents classified as
diabetic by their diabetic offspring (n = 66; 50
Methods
parents of patients with and 16 of patients with-
out nephropathy) and furthermore, in a sample
of 221 (71%) of all 311 presumed non-diabetic
parents (217 parents of patients with and 94
parents of patients without nephropathy). The
sample of 221 presumed non-diabetic parents,
comprising 138 (64%) of patients with and 83
(88%) of patients without nephropathy, was se-
lected as follows: first, their medical history was
obtained from those parents subsequently in-
terviewed at the outpatient clinic when they had
their assessment of oral glucose tolerance (n =
95 and 55). Second, in order to test the reliabil-
ity of data on those presumed non-diabetic par-
ents not attending the outpatient clinic, the
medical record and death certificate validation
procedure was then performed on a subgroup of
71 parents (n = 43 and 28) of whom 18 were
alive (n = 14 and 4) and 53 dead (n = 29 and
24).
Assessment of blood pressure
and hypertension
Systolic (Korotkoff I) and diastolic (Korotkoff
V) office blood pressure was measured ausculta-
torily on the right arm with an ordinary cali-
brated mercury sphygmomanometer (Studies
I to IV) or a Hawksley random zero sphyg-
momanometer (Study I) with a properly sized
cuff after at least 5 min of rest. The mean value
of at least two recordings was used in the
analysis. In Study V, an aneroid sphygmoma-
nometer was employed to measure ausculta-
tory blood pressure after the subject had rested
10 min supine.
In Study I, 24 h ambulatory blood pressure
was measured oscillometrically with a
SpaceLabs 90207 device (SpaceLabs Inc.,
Redmond, WA, USA). The monitor was
checked before, after, and once each month
Methods
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during the study by comparison with a cali-
brated mercury sphygmomanometer accord-
ing to the instructions of the manufacturer.
Blood pressure was measured every 15 min
from 07:00 to 22:00 and every 30 min from
22:00 to 07:00 with a properly sized cuff dur-
ing 24 h of normal daily activities. Blood-
pressure monitoring was accepted if there was
at least one successful blood-pressure record-
ing per hour during at least 20 of the 24 h of
monitoring. Day- and night-time blood pres-
sures were calculated based on individually
recorded awake and sleeping hours.
Hypertension was defined as current use of
antihypertensive medication, an office blood
pressure exceeding or equal to 140/90 (Stud-
ies I, III) or 160/95 mmHg (Study II), or a 24
h ABPM exceeding or equal to 135/85 mmHg
[181, 182].
Assessment of diabetic complications
The degree of renal involvement in the dia-
betic patients was based on at least three urine
collections [183]. Overt diabetic nephropathy was
defined as an UAER exceeding either 200 µg/
min (overnight urine collections) or 300 mg/
24 h (24 h urine collections), and microalbu-
minuria as UAER 20 to 200 µg/min or 30 to
300 mg/24 h in two out of three consecutive
urine collections in the absence of any clini-
cal or laboratory evidence of other renal dis-
ease. Normal UAER was defined as UAER
persistently below 20 µg/min or 30 mg/24 h.
In some patients, UAER had decreased, for
instance after initiation of antihypertensive
therapy. In these cases, classification of mi-
croalbuminuria and overt diabetic nephropa-
thy was based on past UAER recordings.
ESRD was considered present after initiation
of renal replacement therapy (dialysis or kid-
ney transplantation). A history of retinal pho-
tocoagulation served as an indicator of severe
retinopathy.
Assessment of glucose metabolism
An OGTT was performed in Studies II, III,
and V. Plasma glucose and serum insulin were
measured in the morning after a 10 to 12 h
overnight fast and at 30, 60, and 120 min
after ingestion of 75 g of glucose in a volume
of 200 ml of water. Diabetes and impaired
glucose tolerance (IGT) in the OGTT were
defined according to 1985 World Health
Organization criteria [184]. Abnormal glu-
cose tolerance was defined as IGT or diabe-
tes. Incremental area under the curve (AUC)
was calculated according to the trapezoidal
rule.
In order to measure insulin sensitivity, the
short ITT [185] was applied in Study III. Two
intravenous cannulas were inserted, one in a
deep cubital vein and a second in retrograde
position in a dorsal vein of the contralateral
hand. The hand was kept in a heated (+55
°C) box in order to achieve arterialization of
venous blood. After a baseline period of 20 to
30 min, fasting plasma glucose was measured
twice, and an intravenous bolus of short-act-
ing insulin (0.1 IU/kg body weight) was
given. Arterialized venous blood samples for
measurement of plasma glucose level were
drawn every min from 3 to 15 min after the
insulin bolus. After the 15 min test-period, a
glucose infusion was initiated, and the sub-
ject received a meal. The percentage decline
in logarithmically transformed plasma glu-
cose per min during 3 to 15 min after admin-
istration of the insulin bolus was calculated
by least square analysis and expressed as the
K
ITT
-value (%/min).
Assessment of albuminuria in relatives
In Study IV, UAER was measured in the non-
diabetic relatives from a timed overnight urine
collection. In Study V, UAER was measured
from three timed urine collections: (I) overnight,
(II) during an OGTT, and (III) during a
submaximal bicycle ergometer test. In order
to maintain sufficient diuresis, the subjects
were given 600 ml of water to drink during
the OGTT, and approximately 10 ml of wa-
ter per kilogram body weight before the ex-
ercise test was initiated. Prior to the exercise
test, each subject lay for 10 min supine. The
test began at a level of 40 W in male and 30
Methods
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W in female subjects, and the work-load was
increased by 40 W in male and by 30 W in
female subjects every 4 min. The target was
90% of the age-adjusted maximal heart rate
(205 minus age in years divided by 2). Blood
pressure was measured at rest and during the
last min at every work-load level, while heart
rate was being recorded with a pulse-sensor
device at rest and at 1-min intervals during
the test. The test was followed by a 10-min
rest in the supine position, after which the
subject voided the final urine sample.
Assessment of smoking
and anthropometric measurements
Smoking was defined as present smoking of at
least one daily cigarette, cigar, or pipe during
the year prior to participation in the studies.
Body weight (to the closest 0.1 kg) and height
(to the closest cm) were measured in light
clothing. BMI was calculated as weight (kg) /
(height (m)2). Waist circumference was measured
midway between the iliac crest and the low-
est rib and hip circumference at the widest part
of the gluteal region. Waist/hip ratio (WHR)
was calculated as waist (cm)/hip (cm).
Assays
Plasma glucose was measured in duplicate by a
glucose oxidase method (Beckman Glucose
Analyser II, Beckman, Fullerton, CA, USA)
with a coefficient of variation of 1.0%. Serum
insulin was measured by enzyme-linked
immunosorbent assay (ELISA; Dako Diagnos-
tics Ltd, Cambridgeshire, UK) in Study III and
by radioimmunoassay (RIA; Insulin-RIA,
Pharmacia-Upjohn, Uppsala, Sweden) in Study
V with coefficients of variation of 9% and 8%,
respectively. In Studies II to V and in the Finn-
ish subjects in Study I, urinary albumin was
measured by use of RIA (Albumin-RIA,
Pharmacia-Upjohn, Uppsala, Sweden) with a
coefficient of variation of 4%. In the Danish
subjects in Study I, urinary albumin was mea-
sured by ELISA [186]. HbA
1c 
was measured by
high-pressure liquid chromatography with a
normal range of 4.0 to 6.0% (Finland) and 4.1
to 6.1% (Denmark). Serum creatinine was as-
sayed by a kinetic Jaffé method (normal range
in Finland: women 50–110, men 55–115
µmol/l; normal range in Denmark: women 40–
110, men 60–130 µmol/l). Serum cholesterol
(normal range: 3.6–7.0 mmol/l), HDL-choles-
terol (normal range: women 1.10–2.35, men
0.95–2.00 mmol/l) and triglycerides (normal
range: 0.4–1.7 mmol/l) were all measured on
a Hitachi 917 automated analyzer with enzy-
matic colorimetric tests.
Statistical analysis
The significance of difference in categorical
variables between the groups was tested with
the Chi squared test. The significance of dif-
ference in normally distributed continuous vari-
ables was tested with Student’s t-test, while
differences in non-normally distributed vari-
ables were assessed with the Mann-Whitney
U-test or Student’s t-test after logarithmic
transformation. Adjustment for confounding
factors was performed by analysis of covari-
ance. The cumulative incidence of parental
hypertension and overall and cardiovascular
parental death rate was calculated with a life-
table method, which takes into account the vari-
ability in length of follow-up. The significance
of the difference in cumulative incidence and
survival between the two groups was deter-
mined with the logrank test. In order to evalu-
ate the independent association between fa-
milial factors and diabetic nephropathy in
Study II, a multiple forward stepwise logistic re-
gression analysis was performed and the ad-
justed odds ratio (OR) and the 95% confi-
dence interval (95% CI) calculated. A two-
tailed P-value less than 0.05 was considered
statistically significant. Normally distributed
continuous variables are presented as mean±
standard error of mean (SEM) and non-nor-
mally distributed variables as median (range).
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Results
Familial predisposition to
hypertension (I)
Antihypertensive therapy for essential hyper-
tension was being administered to 37 (34%)
of the parents of patients with diabetic neph-
ropathy (DN+) and to 22 (20%) of the par-
ents of patients without diabetic nephropa-
thy (DN–), P < 0.05. Regarding the 162 par-
ents with no antihypertensive treatment, of-
fice blood pressure was measured for all and
24 h ABPM for 131. A successful 24 h ABPM
was obtained for 128 of the parents (55 of
DN+ and 73 of DN–). The 31 parents (14 of
DN+ and 17 of DN–) for whom a 24 h ABPM
was not performed were slightly older (69 vs
66 years; P = 0.034), but did not differ re-
garding sex, BMI, or office blood pressure
from the rest of the parents.
There was no significant difference in of-
fice or 24 h ambulatory blood pressure be-
tween the two groups of parents not receiv-
ing antihypertensive treatment (Table 6).
However, the proportion of parents on anti-
hypertensive medication or with a 24 h am-
bulatory blood pressure  135/85 mmHg was
57% among parents of DN+ and 41% among
parents of DN–, P < 0.05. When office blood
pressure was used to identify parents with
untreated hypertension, the difference in
prevalence of hypertension (antihypertensive
medication or office blood pressure  140/90
mmHg) between parents of DN+ patients and
DN– patients did not reach statistical signifi-
cance (64% vs 57%, P = NS).
The cumulative incidence of hypertension
was higher in parents of patients with DN+
than in parents of patients with DN– (Figure
2).
1.0
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Figure 2. Cumulative incidence of antihypertensive
medication in parents of DN+ (solid line; n=109) and
parents of DN – (hatched line; n = 112). Cumulative
incidence of antihypertensive medication was higher
in parents of DN+ (logrank test: P=0.002).
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Table 6. Office and ambulatory blood pressure (mmHg)
in parents without antihypertensive medication
Office blood pressure
n
Systolic
Diastolic
Ambulatory blood pressure
n
24 h systolic
24 h diastolic
Daytime systolic
Daytime diastolic
Night-time systolic
Night-time diastolic
DN–
90
142±2
82±1
73
126±1
74±1
131±2
79±1
115±2
65±1
DN+
72
141±2
83±1
55
126±2
76±1
131±2
81±1
116±2
67±1
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After inclusion of data on non-attending
parents furnished by their participating
spouses, absence or presence of antihyperten-
sive medication could be determined in both
parents of 63 (86%) DN+ patients and of 68
(93%) DN– patients. A parental history of
hypertension was more common among DN+
patients (56% vs 29%, P < 0.01). In addi-
tion, among DN+ patients, parental antihy-
pertensive therapy was associated with in-
creased risk for systemic hypertension in the
patients themselves (Figure 3).
No difference existed in prevalence of car-
diovascular disease between parents of DN+
and DN– patients (21% vs 18%, P = NS),
whereas diabetes was more common in par-
ents of DN+ patients than in those of DN–
patients (16% vs 8%, P = 0.034).
Familial predisposition to diabetes (II)
The reliability of the information obtained
from diabetic patients was tested by inter-
viewing a subgroup of parents and by review-
ing the medical records and death certificates
of a subgroup of deceased parents. The pa-
tients had identified parental diabetes with a
specificity of 93% and a sensitivity of 100%.
The corresponding figures for parental hyper-
tension were 89% and 90%, respectively, and
for parental death from cardiovascular causes
83% and 97%. Since the main objective was
to assess the impact of a family history of dia-
betes on the development of diabetic nephr-
opathy, only confirmed cases of parental dia-
betes were included in the analysis, while pa-
tient reported data were used regarding pa-
rental hypertension and cardiovascular death.
At the time of the study, 39% and 32% of
the parents of patients with DN+ and DN–
were deceased (P = NS) with thus no signifi-
cant difference in proportion of those deceased.
However, a survival analysis taking into ac-
count the time of follow-up (that is, age at
death, or age at the time of the study) revealed
impaired survival in parents of DN– patients
(logrank test: P < 0.05). No significant dif-
ference was found in cardiovascular death rate
between the parents in the two groups, al-
though there was a tendency towards higher
cardiovascular death rate among mothers of
DN+ patients than mothers of DN– patients
(P = 0.095) in a sex-stratified analysis.
Diabetes was more prevalent among par-
ents of DN+ patients (16% vs 6%, P < 0.01),
mostly due to an excess in type 2 diabetes
(14% vs 6%, P < 0.05). In addition, there
was an excess of hypertension in parents of
DN+ patients (36% vs 19%, P < 0.01). Pa-
rental history of type 2 diabetes and hyper-
tension, gender, diabetes duration, smoking,
and HbA
1c
 were entered into a forward
stepwise multiple logistic regression analysis
(Table 7). In addition to glycemic control and
male gender, parental history of type 2 diabe-
100
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Figure 3. Proportion of patients with DN+ treated for
hypertension in relation to antihypertensive treatment
in neither, one, or both parents. Hypertension was
more common in patients with hypertension in both
parents compared to patients without parental
hypertension (100% vs 61%, P<0.05).
Table 7. Adjusted odds ratios (OR) for variables
independently associated with diabetic nephropathy
Variable
HbA1c
Parental type 2 diabetes
Male sex
Parental hypertension
OR (95% CI)
1.76 (1.29–2.40)
2.95 (1.03–8.40)
2.30 (1.13–4.67)
2.06 (1.00–4.24)
P
<0.01
<0.05
<0.05
<0.05
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tes and hypertension were both independently
associated with diabetic nephropathy.
An OGTT was performed in parents with
no history of diabetes (Tables 5 and 8). Par-
ents of patients with nephropathy had higher
fasting plasma glucose levels and had more
often been treated for hypertension. Fathers
of DN+ patients also had higher WHR than
fathers of DN– patients.
Familial abnormalities in glucose
metabolism (III)
No differences in insulin sensitivity or in in-
sulin secretion were discernible between rela-
tives of DN+ and DN– patients (Table 9).
The relatives of the DN+ showed an excess of
hypertension (46% vs 29%, P < 0.05) and
more frequently a family history of type 2
diabetes (34% vs 20%, P < 0.05) than did
relatives of the DN–. Selection of one relative
at random for each diabetic patient did not
influence the results (DN+ vs DN–: K
ITT
4.0±0.2 vs 3.9±0.1 %/min, P = NS; ratio of
insulin AUC/glucose AUC 21.1±4.0 vs
22.1±4.0, P = NS).
Twenty-five relatives of patients with DN+
and 13 relatives of patients with DN– had
abnormal glucose tolerance (IGT or diabetes;
Table 10). Relatives of DN+ patients were
younger. As shown in Table 11, no difference
existed in insulin sensitivity between the two
groups of glucose-intolerant relatives. How-
ever, their insulin response to a rise in plasma
glucose (insulin AUC/glucose AUC-ratio) in
the OGTT was impaired among relatives of
DN+ patients (Table 11). This difference in
insulin secretion between relatives of DN+
Table 8. Characteristics of parents with no history of diabetes
Variable
Fathers/mothers
Age (years)
WHR, fathers
WHR, mothers
BMI, fathers (kg/m2)
BMI, mothers (kg/m2)
Fasting plasma glucose (mmol/l)
Glucose AUC (mmol/l × min)
Abnormal glucose tolerancea (%)
Antihypertensive therapy (%)
DN+
n=95
36/59
65±1
0.97±0.01
0.85±0.01
28.0±0.7
28.4±0.6
5.7±0.1
326±18
33
34
DN–
n=55
22/33
65±1
0.94±0.01
0.83±0.01
26.1±0.9
27.9±0.7
5.4±0.1
300±21
24
18
P
NS
NS
<0.05
NS
<0.05
NS
<0.05
NS
NS
<0.05
aIGT or diabetes
Table 9. Plasma glucose and serum insulin response to oral glucose load and insulin sensitivity measured in first-
degree relatives of DN+ and DN–
Variable
Fasting plasma glucose (mmol/l)
Fasting serum insulin (mU/l)
Glucose AUC (mmol/l × min)
Insulin AUC (mU/l × min)
Insulin AUC/glucose AUC-ratio
KITT (%/min)
a
Relatives of DN+
(n=114)
5.3±0.1
5±1
276±16
3349±248
17.9±1.9
4.0±0.1
Relatives of DN–
(n=93)
5.3±0.1
5±1
225±12
3380±280
17.8±1.9
4.2±0.1
P
NS
NS
NS
NS
NS
NS
aMeasured in 101 and 84 relatives of DN+ and DN–, respectively.
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and DN– patients was already discernible at
the IGT stage (Figure 4).
Familial abnormalities in urinary
albumin excretion rate (IV–V)
Study IV
The two groups of relatives participating were
comparable regarding sex distribution, age,
BMI, and prevalence of smoking (Table 5).
Similarly, no difference existed in blood pres-
sure (systolic: 138±2 vs 138±3 mmHg, P =
NS; diastolic 84±1 vs 84±2 mmHg, P = NS),
prevalence of antihypertensive treatment
(17% vs 13%, P = NS), or serum creatinine
concentration (80 [44–128] vs 80 [57–112]
µmol/l, P = NS) between relatives of patients
who were DN+ and DN–, respectively. Over-
night UAER did not differ between relatives
of DN+ and DN– patients (Figure 5). The
proportion of relatives with a UAER  10 µg/
min was 12% for the DN+ compared to 8%
for the DN– (P = NS). Stratified analyses of
males and females as well as of parents and
siblings revealed no difference in UAER be-
tween the two groups (Table 12).
Table 10. Characteristics of relatives with abnormal glucose tolerance
Variable
Sex (M/F)
Age (years)
BMI (kg/m2)
WHR male subjects
WHR female subjects
Hypertension (%)
Smoking (%)
HbA1c (%)
Proportion IGT/diabetes
Relatives of DN+
(n=25)
9/16
57±3
28.1±0.9
1.00±0.03
0.84±0.02
74
16
5.6±0.1
18/7
Relatives of DN–
(n=13)
6/7
66±2
28.5±1.3
0.98±0.02
0.87±0.02
46
23
5.8±0.1
9/4
P
NS
0.027
NS
NS
NS
0.049
NS
NS
NS
Table 11. Insulin sensitivity and insulin secretion in relatives with abnormal glucose tolerance
Variable
KITT (%/min)
a
Fasting plasma glucose (mmol/l)
Fasting serum insulin (mU/l)
Glucose AUC (mmol/l × min)
Insulin AUC (mU/l × min)
Insulin AUC/glucose AUC-ratio
Relatives of DN+
(n=25)
3.3±0.2
5.8±0.1
7±1
493±36
4089±744
8.9±1.4
Relatives of DN–
(n=13)
3.2±0.3
5.7±0.1
8±1
387±38
6209±1396
16.8±3.9
P
NS
NS
NS
NS
NS
0.039
aPerformed in 23 and 11 relatives of patients with DN+ and DN–, respectively.
Table 12. UAER (µg/min) in subgroups of relatives in
Study IV
Subgroup
Male
Female
Parents
Siblings
DN+
3.4 (0.1–372)
3.5 (0.2–118)
3.5 (0.1–372)
3.4 (0.2–118)
DN–
4.2 (1.1–24.3)
3.5 (0.2–61.5)
4.0 (0.2–61.5)
3.6 (0.4–14.4)
P
NS
NS
NS
NS
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Of relatives of DN+ patients, 32 (17%)
were treated for hypertension, and the corre-
sponding number for relatives of the DN– was
7 (13%; P = NS). Among relatives of the
DN+, those on antihypertensive treatment
had a higher UAER than did those without:
5.0 (0.5–372) vs 3.4 (0.1–26.5) µg/min; P <
0.01. A similar phenomenon was absent from
relatives of the DN–, where UAER was com-
parable in relatives with and without treat-
ment for hypertension: 3.6 (2.1–24.3) vs 4.0
(0.2–61.5) µg/min; P = NS. In order to assess
Figure 4. Serum insulin and plasma glucose levels in
relatives with impaired glucose tolerance (IGT). The insulin
secretion (insulin AUC/glucose AUC-ratio) was impaired
in IGT-relatives of DN+ compared to IGT-relatives of
DN–  (9.3±1.7 vs 16.2±3.4, P=0.058), with no difference
observed in insulin sensitivity between these two groups
(3.6±0.2 vs 3.6±0.3 %/min, P=NS).
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Figure 6. UAER in relatives of patients with DN+ and
DN– divided into age tertiles. The tertiles correspond
to an age below 43 years (I), between 43 and 62 years
(II), and above 62 years (III).
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Figure 5. Logarithmically transformed UAER in relatives
of patients with DN+ and DN–. There was no difference
in UAER between relatives of DN+ and DN– (3.4
[0.1–372]  vs 4.0 [0.2–62] µg/min, respectively; P =
NS).
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was observable in any of the tertiles. In order
to control for the range in number of rela-
tives studied per diabetic patient, one rela-
tive per diabetic patient was randomly se-
lected. In this analysis, no difference in UAER
was observed between the two groups: DN+
(n = 80) vs DN– (n = 25): 3.6 (0.1–168) vs
3.6 (0.2–61.5) µg/min; P = NS.
Study V
As a result of the matching procedure, the
two groups of siblings participating in Study
V were similar regarding age, gender, BMI,
and smoking habits (Table 5). Furthermore,
no significant differences were apparent in
serum creatinine, blood pressure levels, or
plasma glucose or serum insulin levels in the
OGTT (Table 13). All siblings had normal
glucose tolerance except for one sister of a
DN+ patient with IGT. UAER measured
from timed urine collections performed over-
night, during the OGTT, and during the
submaximal exercise test did not differ be-
tween the two groups of relatives (Figure 7).
Furthermore, the exercise-induced propor-
tional increase in UAER was approximately
eight-fold in both groups of siblings; DN+
vs DN–: 8.3 (2.1–193) vs 7.9 (1.7–119)-fold
increase; P = NS.
any effect of impaired survival among rela-
tives of patients with nephropathy, the rela-
tives were further divided into tertiles accord-
ing to age (Figure 6). No difference in UAER
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Figure 7. Logarithmically transformed UAER in siblings
of patients with DN+ and with DN–. There was no
significant difference between siblings of patients with
DN+ and DN– in UAER measured overnight: median
(range): 3.8 (1.3–24.1) vs 3.5 (2.0–21.0) µg/min; P=
NS, during the OGTT 6.3 (3.2–26.0)] vs 4.8 (1.9–15.7)
µg/min; P = NS or during the exercise test 44.8
(7.0–535) vs 30.0 (3.4–1614) µg/min; P=NS.
Table 13. Renal function, blood pressure, and glucose metabolism in siblings of patients with DN+ and DN– in Study V
Variable
Serum creatinine (µmol/l)
Systolic blood pressure (mmHg)
Diastolic blood pressure (mmHg)
Fasting plasma glucose (mmol/l)
Glucose AUC (mmol/l × min)
Fasting serum insulin (mU/l)
Insulin AUC (mU/l × min)
DN+
(n=21)
78±2
125±2
76±2
5.1±0.1
125±27
7±1
4282±690
DN–
(n=24)
82±3
124±3
76±3
5.0±0.1
135±26
6±1
3644±801
P
NS
NS
NS
NS
NS
NS
NS
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Discussion
Subjects and methods
The Finnish patients were recruited from the
nephrological unit and the diabetic outpatient
clinic of the Helsinki University Central Hos-
pital as well as from among members of the
Helsinki Diabetes Association, and the Dan-
ish patients in Study I from the outpatient
clinic of the Steno Diabetes Center in
Gentofte, but in both countries the health care
systems as well as the epidemiology of type 1
diabetes [187] and its long-term complica-
tions [2, 188] are very similar. It is therefore
unlikely that the inclusion of patients from
two different source populations in Study I
would cause problems in terms of validity of
the results. Most of the patients with type 1
diabetes residing in the Copenhagen area are
treated at the Steno Diabetes Center. Simi-
larly, Helsinki University Central Hospital
runs the only nephrological unit in the
Helsinki area. Patients from these sources can
be considered representative of type 1 diabetic
patients with long-duration diabetes with and
without diabetic nephropathy. In addition,
patients came from the diabetic outpatient
clinic of the Helsinki University Central Hos-
pital and via an advertisement in the news-
letter of the Helsinki Diabetes Association.
These patients could have been affected by
some selection bias: first, complicated cases
are more easily referred to a university hospi-
tal; second, members of a diabetes association
can be assumed to be more actively involved
in gaining knowledge of their disease than
the average diabetic patient. However, as the
aim of the present studies was to assess the
effect of familial traits on the development of
diabetic nephropathy, it is highly unlikely that
any selection bias would have had an effect
on occurrence of familial traits in patients with
and without diabetic nephropathy. In terms
of familial factors, the patients included in
this study are therefore most likely represen-
tative of Caucasian type 1 diabetic patients
with and without diabetic nephropathy.
In Study I, 24 h ABPM was used to mea-
sure parental blood pressure in addition to
office blood pressure. The SpaceLabs 90207
24 h ABPM device achieved a B-rating [189]
when tested according to the British Hyper-
tension Society Protocol [190] and was con-
sequently recommended by the authors for
measurement of 24 h ambulatory blood pres-
sure. Day- and night-time blood pressures
were calculated by use of individually recorded
waking and sleeping hours [191]. Most stud-
ies have reported a better correlation with end-
organ damage [192–194] and a better pre-
dictive value for future cardiovascular events
[195] and for treatment-induced regression
of left ventricular hypertrophy [196] with 24
h ABPM than with conventional office blood
pressure. Thus, 24 h ABPM is considered su-
perior to conventional blood pressure in iden-
tifying subjects with clinically relevant hy-
pertension. This superiority is even more pro-
nounced if office blood pressure is measured
on a single occasion, since high screening val-
ues tend to overestimate and low screening
values underestimate true blood pressure, a
phenomenon referred to as regression dilution
bias [197]. At present, little information is
available from prospective studies on the cut-
off level for hypertension in 24 h ABPM, but
in Study I we applied the operational thresh-
old for hypertension (  135/85 mmHg) pro-
posed by Staessen et al [181] and the Ameri-
can Society of Hypertension [182].
In Study III, whole-body insulin sensitiv-
ity was measured with the short ITT [185].
When glucose disappearance rate is measured
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from arterialized venous blood as was the case
in Study III, the index of insulin sensitivity
in the short ITT (the K
ITT
-value) has been
found to correlate well (r > 0.8) with insulin
sensitivity measured with the gold standard:
the insulin clamp technique [185]. Performed
in this way, the short ITT has been found to
be reproducible with coefficients of variations
of 6 to 13% [185, 198].
Parental mortality
In a family study by Earle and co-workers
[136], increased mortality was found among
parents of type 1 diabetic patients who showed
elevated UAER compared to that of parents
of patients with normal UAER. This was
mostly due to an excess of parental cardiovas-
cular mortality. This finding was, however,
not confirmed by a Danish study [143], but
it is worth noting that the number of patients
involved in both studies was rather small.
In Study II, we found survival to be im-
paired among parents of patients with neph-
ropathy. In support of this view, two other
recent studies have confirmed increased mor-
tality rates among parents of patients with
nephropathy when assessed by survival analy-
sis [199, 200]. Both studies found an excess
of cardiovascular mortality in such parents
[199, 200], especially an increase in death
from stroke in one [199]. In Study II, there
was a tendency towards increased cardiovas-
cular mortality rate among mothers of patients
with nephropathy compared to mothers of
patients without nephropathy. No difference
Discussion
Table 14. Parental hypertension (HT) or blood pressure (BP) and development of diabetic nephropathy (DN) in type 1 diabetes
History of hypertension
Krolewski 1988a [132]
Barzilay 1992a [133]
Molitch, 1993a [201]
Rudberg 1998a [202]
Earle 1992b [136]
Tarnow 1998b [200]
Study IIb
EURODIAB 1998 [203]
Office BP
Viberti 1987 [131]
Walker 1990 [135]
Office BP + AHT
Jensen 1990 [134]
De Cosmo 1997 [205]
Verhage 1999 [206]
24h ABPM + AHT
Study I
No of patients with
DN+
33
43
73
75
61
163
137
≈1000
17
20
49
31
29
73
DN–
56
61
642
225
61
163
54
≈2250
17
20
49
31
28
73
Parental HT or BP in
DN+
77%
70%
39%
29%
21%
27%
36%
– c
122±17
99 (77–121)
25%
42%
16%
57%
Definition
of DN+
(UAER)
>70 µg/min
>250 µg/min
>28 µg/min
>15 µg/min
>30 µg/min
>300 mg/24h
>200 µg/min
>20 µg/min
>0.15 g/l
>150 µg/min
>300 mg/24h
>45 µg/min
>20 µg/min
>200 µg/min
DN–
45%
38%
40%
8%
14%
24%
19%
– c
111±11
98 (89-118)
19%
14%
20%
41%
Association
between
parental
HT and DN
Yes
Yes
No
Yes
No
No
Yes
Yes
Yes
No
No
Yes
No
Yes
aProportion of diabetic patients with a history of parental hypertension. bPrevalence of hypertension in the parents.
cNo prevalence estimate of parental hypertension available, but a family history of hypertension was associated
with an age-adjusted odds ratio for albuminuria of 1.3. Note that regarding the patients included, there is an
overlap between studies [132] and [133], [200] and [134], [200] and Study I, and Study I and Study II.
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was evident in cardiovascular death rate in
fathers alone or in all parents, and we could
confirm no particular increase in deaths from
stroke among parents of patients with nephr-
opathy (data not shown). However, Study II
did not have the same power as the other re-
cent studies [199, 200]. Thus, diabetic neph-
ropathy in type 1 diabetic patients is associ-
ated with impaired survival in the parents, a
phenomenon that seems to be due to an ex-
cess of cardiovascular disease.
Familial predisposition to hypertension
Viberti and co-workers [131] were the first
to report an association between high blood
pressure in non-diabetic parents and pro-
teinuria in their offspring with type 1 diabe-
tes. Retrospective analysis of a family study
conducted in the 50’s revealed a higher arte-
rial blood pressure in 26 parents of 17 pa-
tients with a urinary protein concentration
exceeding 0.15 g/l than in 26 parents of 17
non-proteinuric patients. This led the authors
to put forward the hypothesis that suscepti-
bility to diabetic nephropathy is linked to a
familial predisposition to hypertension. How-
ever, at the time Study I was initiated, a con-
troversy existed regarding this subject, with
some studies supporting the original obser-
vation [132, 133], and others unable to find
higher blood pressure [134, 135] or an excess
of hypertension [136, 201] in parents of pa-
tients with signs of diabetic nephropathy.
Table 14 presents an update of studies pub-
lished thus far dealing with the subject. These
exhibit huge variation in sample size, and
their definitions of diabetic nephropathy range
from the upper level of normoalbuminuria in
a Swedish study on pediatric patients [202]
to ESRD because of diabetic nephropathy, as
in Study II. The methods of determining fa-
milial hypertension vary from assessing pa-
rental history of hypertension [132, 133, 136,
200–204], to measuring parental office blood
pressure [131, 135], to combining antihyper-
tensive medication and office blood pressure
[134, 205, 206] or 24 h ABPM [207] in or-
der to calculate total prevalence of parental
hypertension. There is an overlap between
some of the studies.
At first glance, the results of the studies
seem to diverge substantially, but a more de-
tailed analysis enables some conclusions to be
drawn. First, although the difference in pa-
rental history of hypertension between pa-
tients with and without nephropathy is not
statistically significant in all studies, there is
indeed an evident overall tendency toward an
excess of hypertension among parents of pa-
tients with nephropathy. The results of the
large EURODIAB study [203] speak in fa-
vor of such a view. Second, studies relying on
office blood pressure may be hampered by
obvious methodological shortcomings, as pre-
viously discussed. Since no routine treatment
for hypertension was available when blood
pressure was measured by Viberti et al [131],
this may explain why the same group detected
no difference in a subsequent study authored
by Walker et al [135]. Regarding hyperten-
sion defined as office blood pressure or as an-
tihypertensive treatment, only one of four
studies [134, 205–207] demonstrates a sig-
nificant difference between parents of patients
with and without nephropathy. The relatively
high prevalence of hypertension in Study I
can be explained by a lower cut-off level (140/
90 mmHg) for untreated hypertension than
in two of the other studies (160/95 mmHg)
[134, 206] and to the fact that the parents in
Study I were older than in the other studies.
Study I is the only study having used 24 h
ABPM to identify parents with untreated
hypertension. In conclusion, an excess of fa-
milial hypertension appears in type 1 diabetic
patients with diabetic nephropathy, but in
order to detect this excess, proper evaluation
of parental blood pressure status and sufficient
statistical power are required.
Thus far, Study I is also the only study
making any attempt to evaluate severity of
hypertension by taking into account the age
of onset of parental hypertension. Parents of
patients with diabetic nephropathy showed
an increased cumulative incidence rate of hy-
pertension, and a pronounced excess of hy-
pertension with a rather young age at onset
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(Figure 2). Two studies on adolescent [202]
and pediatric patients [137] support these
findings. In the study by Rudberg et al [202],
a parental history of hypertension was associ-
ated with a four-fold risk for micro- or mac-
roalbuminuria in the offspring. Likewise,
Freire and co-workers [137] found that among
normoalbuminuric patients with an UAER
in the highest tertile, 79% had a family his-
tory of hypertension compared to only 29%
of patients with UAER in the lowest tertile.
Based on the patients’ age, the mean age of
the parents in these studies must have been
low, and both report strong associations be-
tween elevated UAER and parental hyperten-
sion. Thus, a familial predisposition to a phe-
notypically more severe hypertension, mani-
fested in the parents at a relatively young age,
may be of particular importance as a deter-
minant of renal outcome in patients with type
1 diabetes. However, before drawing any fur-
ther conclusions in terms of identifying high-
risk patients, our hypothesis needs to be tested
in large-scale prospective study settings.
Hypertension was more often present in
those patients suffering from nephropathy
who had a parental history including antihy-
pertensive therapy. Although this finding
must be regarded as preliminary because com-
parisons were made between relatively small
groups, it suggests that for patients with dia-
betic nephropathy, a familial predisposition
to hypertension is associated not only with
their increased risk for diabetic nephropathy,
but also with their increased risk for systemic
hypertension.
Why would a predisposition to hyperten-
sion increase risk for nephropathy in type 1
diabetes? The importance of hemodynamic
factors in the genesis of diabetic nephropathy
has been discussed above. It is of interest that
a family history of hypertension has been as-
sociated both with elevated systemic blood
pressure and with increased glomerular fil-
tration in recent-onset type 1 diabetic patients
as well as in non-diabetic subjects [208, 209].
Of these abnormalities, glomerular hyperfil-
tration may be more important in the initia-
tion of renal damage, since such hyperfiltra-
tion [96] is a more powerful predictor of sub-
sequent microalbuminuria or overt diabetic
nephropathy than is the level of systemic
blood pressure [24, 96, 104, 105]. However,
at a later stage, the level of systemic blood
pressure is strongly positively correlated with
the rate of decline in renal function.
Familial predisposition to diabetes
In Pima Indians, diabetic nephropathy in the
parents, more than parental diabetes alone,
has been associated with an increased risk for
diabetes in the offspring [152], suggesting a
link between familial diabetes and develop-
ment of diabetic nephropathy. Studies in type
1 diabetes evaluating parental hypertension
[131, 134, 135, 202] and prevalence [136,
143, 200] or mechanisms [205, 206] of pa-
rental cardiovascular disease, have not re-
ported any excess of parental diabetes in type
1 diabetic patients with nephropathy. How-
ever, these studies have in general been small.
Support of our observation in Study II comes
from two recent large-scale studies. An asso-
ciation between parental diabetes and albu-
minuria in the type 1 diabetic offspring was
observed in the EURODIAB Study [203]. In
the Pittsburgh Epidemiology of Diabetes
Complications Study [210], the prevalence of
nephropathy was significantly higher in
univariate analysis among type 1 diabetic pa-
tients with familial type 2 diabetes than in
those without.
In Study II, parental type 2 diabetes was
associated with an almost three-fold risk for
nephropathy in the offspring, which exceeds
the 95% CI of the EURODIAB Study [203].
Additionally, in the EURODIAB Study, the
finding was limited to female patients alone,
whereas the association in male patients, af-
ter adjustment for glycemic control, failed to
reach statistical significance. However, the
classification of patients into albuminuric and
normoalbuminuric in the EURODIAB Study
was based on a single urine collection, and
the control group had had a relatively short
diabetes duration and could therefore have
included some proportion of patients at con-
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siderable risk for subsequent development of
nephropathy. Misclassification of cases and
controls in a study with a case-control design
will lead to an underestimation of any associ-
ated phenomenon. Therefore, the stronger
association between diabetic nephropathy and
parental diabetes found in our Study II is most
likely a result of the more robust classifica-
tion of cases and controls we used.
In the insulin resistance syndrome, hyper-
tension and abnormalities of glucose metabo-
lism are closely intertwined [14], so that an
association of diabetic nephropathy with pa-
rental diabetes may be just another reflection
of its association with parental hypertension.
However, the association of diabetic nephr-
opathy with a family history of diabetes was
independent of that of a family history of hy-
pertension in Study II, which was also the case
in the EURODIAB Study [203]. Therefore,
a family history of diabetes and familial pre-
disposition to hypertension seem to influence
the risk of nephropathy via different mecha-
nisms.
In order to identify the mechanisms link-
ing a family history of diabetes to diabetic
nephropathy in type 1 diabetes, a further char-
acterization of the mechanisms behind the
familial clustering of diabetes is needed. The
two key variables involved in the regulation
of glucose metabolism are insulin sensitivity
and insulin secretion [211]. Study II found a
particular excess of parental type 2 diabetes,
defined as all cases of diabetes other than those
with their onset before age 40 and that had
been treated with insulin alone, but it is evi-
dent that this definition will include cases of
diabetes with a wide range of different etio-
logic mechanisms [212]; it is thus impossible
to further characterize the pathogenetic
mechanisms based on this observation.
Impaired insulin sensitivity has been found
present in the early stages of diabetic nephr-
opathy in both type 1 [146, 147, 213] and
type 2 diabetes [150, 214]. This impairment
in insulin sensitivity has in part been attrib-
uted to genetic factors, since insulin resistance,
either based on fasting hyperinsulinemia
[153] or measured with the short ITT [205],
has been found present in relatives of type 1
diabetic patients with micro- or macroalbu-
minuria. Furthermore, assessment of the non-
diabetic parents participating in Study II re-
vealed, in parents of patients with diabetic
nephropathy, an excess of abdominal obesity,
higher fasting plasma glucose, and more hy-
pertension – all factors associated with the
insulin resistance syndrome [14]. However,
in Study III, we found no significant impair-
ment of insulin sensitivity in non-diabetic
relatives of patients with nephropathy com-
pared to that in relatives of patients without
nephropathy, despite Study III’s being the
largest one thus far that has addressed this
question.
Differences in study design may explain
some of this discrepancy. Study III focused
only on relatives with normal fasting blood
glucose, and this differs from the strategy
applied by De Cosmo and coworkers, who also
included diabetic parents [205]. In Study III,
there was an excess of diabetes among rela-
tives of patients with nephropathy, and ex-
clusion of these diabetic individuals most
likely resulted in an underestimation of the
true abnormalities in glucose metabolism in
this group. However, chronic hyperglycemia
has well-known effects on glucose metabo-
lism, including an impairment in both insu-
lin sensitivity and insulin secretion [215]. If
we had included diabetic relatives in Study
III, we would have been unable to exclude
the fact that any impairment observed in, for
instance, insulin sensitivity was merely a con-
sequence of their chronic hyperglycemia. Fo-
cusing on those relatives without severe hy-
perglycemia offered us an opportunity to iden-
tify the underlying mechanisms of the excess
of diabetes in relatives of patients with neph-
ropathy.
Moreover, De Cosmo’s group [205] ob-
served parents alone, not, as in the present
study, all first-degree relatives. Indeed, in
Study III, insulin sensitivity tended to be
impaired, especially in fathers of patients with
nephropathy (K
ITT
 2.9 vs 3.7%/min, respec-
tively). We measured insulin sensitivity with
the short ITT, a method found to be both re-
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liable and reproducible in estimating whole-
body insulin sensitivity [185, 198]. However,
one cannot ignore the fact that the use of more
sophisticated methods, for instance the insu-
lin clamp technique, could have detected a
difference in insulin sensitivity between the
two groups. A role for impaired insulin sen-
sitivity cannot, therefore, be excluded in the
familial clustering of diabetes in patients with
nephropathy, but if impaired insulin sensi-
tivity does play a major role, one would have
expected it to be detected with our sample
size, despite these various shortcomings. An-
other recent study found, in parents of pa-
tients with nephropathy, no clustering of fac-
tors associated with the metabolic syndrome
[206].
The new finding in Study III was impaired
insulin secretion in relatives of patients with
nephropathy, a finding not evident when as-
sessed in all relatives, but isolated in relatives
with signs of abnormal glucose tolerance. Since
this was the result of a post-hoc analysis, the
finding should be interpreted with caution.
It is, however, rational to focus on those rela-
tives with evidence of mild abnormalities in
glucose metabolism, since only a minority of
all the relatives in this study will ever develop
diabetes, and the mechanisms responsible for
an excess of familial diabetes in patients with
nephropathy will most likely be found in that
group. In this respect, it is noteworthy that
insulin response to a glucose load is related to
degree of derangement of glucose metabolism,
with a more marked hypoinsulinemia as the
degree of hyperglycemia increases [216]. The
question arises, whether the impairment of
insulin secretion observed is a primary phe-
nomenon, or whether it is just a consequence
of subclinical hyperglycemia. Although the
latter is possible, it should be emphasized that
all the relatives studied had only mild abnor-
malities in glucose metabolism – in fact, they
would all have been classified as non-diabetic
based on their fasting plasma glucose level.
Furthermore, no differences existed between
the groups in the proportions of IGT and dia-
betes, or in the level of HbA
1c
. Finally, al-
though based on comparison between very
small groups, the impairment in insulin se-
cretion in relatives of patients with nephropa-
thy was already present at the stage of IGT.
Therefore, even though our results are prelimi-
nary and need to be confirmed, they suggest
that the excess of diabetes in the family his-
tory for type 1 diabetic patients with nephr-
opathy at least in part may be due to a pri-
mary, possibly inherited, impairment in insu-
lin secretion.
By what mechanism could such familial
abnormalities increase the risk for diabetic
nephropathy in the type 1 diabetic patient?
First, patients with an inherited tendency to-
ward impaired insulin sensitivity may be at
increased risk for nephropathy since good
metabolic control is likely to be more diffi-
cult to achieve in such patients. They may also
require higher doses of exogenous insulin, and
the resultant hyperinsulinemia may increase
UAER via increased endothelial permeability
[217] or via effects on glomerular hemody-
namics [218, 219]. Factors associated with
impaired insulin sensitivity, such as hyperten-
sion [220] and dyslipidemia [221], may also
exert deleterious effects on the glomerulus.
Second, type 1 diabetic patients with re-
sidual endogenous insulin secretion are at
lower risk of diabetic microvascular compli-
cations than are patients with complete loss
of beta-cell function [179]. An inherited in-
sulin-secretion defect may increase risk for
nephropathy by causing a more complete loss
of beta-cell function at the time of onset of
diabetes. This could simply result in worse
metabolic control, with harmful effects on the
kidneys. However, beneficial effects of c-pep-
tide on renal function have also been described
[222], and the absence of circulating c-pep-
tide could thereby increase risk for diabetic
nephropathy. Furthermore, gestational diabe-
tes develops when the beta cells are unable to
respond to the increased need for insulin due
to the insulin resistance induced by pregnancy
[223]. The recent observation in Pima Indi-
ans that offspring of mothers who have dia-
betes during their pregnancy are at increased
risk for elevated UAER [224] may provide
an additional mechanism for an increased risk
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for nephropathy in patients with familial de-
fects in insulin secretion, because intrauter-
ine hyperglycemia exerts detrimental effects
on fetal kidney function [225].
In the light of our findings, several ques-
tions need to be answered in large-scale study
settings for type 1 diabetic patients. First, is
it possible to confirm that preserved beta-cell
function protects against development of dia-
betic nephropathy? If so, is this just an effect
of enhanced metabolic control, or is there per-
haps some protective effect from the c-pep-
tide molecule? Second, what is the relation
between familial diabetes and residual beta-
cell function in the type 1 diabetic patient?
Third, is there any association between ma-
ternal gestational diabetes and development
of diabetic nephropathy in the offspring? The
answers to these questions will determine the
importance of our finding of impaired insu-
lin secretion in glucose-intolerant relatives of
patients with elevated UAER.
Familial abnormalities in urinary
albumin excretion rate
Studies in both type 1 [6, 120, 121, 123] and
type 2 diabetes [124, 126, 127] have reported
familial clustering of microalbuminuria and/
or proteinuria in diabetic siblings. Thus, in
the presence of diabetes, genetic factors seem
to influence UAER. Several family studies
have reported an elevated UAER also in non-
diabetic relatives of those type 2 diabetic pa-
tients showing micro- or macroalbuminuria
when compared with that in relatives of
normoalbuminuric patients [126, 128–130].
Therefore, at least for relatives of type 2 dia-
betic patients, abnormalities leading to an el-
evated UAER seem to be present even in the
absence of diabetes in subjects with a poten-
tial genetic susceptibility to diabetic nephr-
opathy. Studies IV and V thus far offer the
only such data available in type 1 diabetes and
indicate that similar abnormalities in UAER
are absent from non-diabetic relatives of pa-
tients with type 1 diabetes and nephropathy.
Since there was no difference in UAER
between relatives of patients with and with-
out nephropathy, the power to detect such a
difference is of crucial importance. Assum-
ing that the distributions of UAER in both
groups were similar to those observed, Study
IV would have detected a relatively small dif-
ference in median value between the two
groups (5.1 µg/min in relatives of DN+ vs
4.0 µg/min in relatives of DN– patients).
Studies performed in type 2 diabetes [126,
128, 129] have reported clearly elevated (ap-
proximately 2-fold) UAER in non-diabetic
relatives of patients with nephropathy com-
pared to that in relatives of patients without
nephropathy. A recent study of relatives of
Finnish type 2 diabetic patients found this
difference to be somewhat smaller [130]. Al-
though our study cannot totally exclude a
minimal elevation in UAER in non-diabetic
relatives of type 1 diabetic patients with neph-
ropathy, it seems justified to question the rel-
evance of an elevation in UAER in such rela-
tives not detected in a sample of our size.
Features associated with elevated albumin-
uria such as cardiovascular morbidity and
mortality [226, 227], diabetes [228], insulin
resistance [229], and hypertension [230] have
all been found to cluster in family members
of type 1 diabetic patients with diabetic neph-
ropathy [131, 136, 153, 203, 204, 207].
Therefore, since we studied UAER in surviv-
ing non-diabetic relatives in Study IV and in
non-diabetic siblings with no antihyperten-
sive therapy in Study V, an underestimation
of the “true” UAER in relatives of type 1 dia-
betic patients with nephropathy may have
taken place. However, also in type 2 diabetes,
relatives of patients with nephropathy are at
increased risk for hypertension [231] and dia-
betes [152] compared to relatives of patients
without nephropathy. Most importantly, the
original observation by Gruden et al [128]
was made in a case-control study with 20 off-
spring in each group, all of whom were nor-
motensive and had normal glucose tolerance.
The confirming observation by Strojek et al
[129] was also based on offspring selected to
be normotensive and to have normal oral glu-
cose tolerance. The studies on siblings of type
2 diabetic patients [126, 130] may readily
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have been affected by selective mortality. In
other words, a similar selection bias is likely
to affect all the studies in type 2 diabetes.
Therefore, the most likely explanation for the
discrepancy between ours and the previous
findings is that a true difference exists between
mechanisms regulating UAER in non-dia-
betic relatives of type 1 and type 2 diabetic
patients.
In Study V, the relatives selected were those
not receiving antihypertensive therapy, nor
was any difference observed in the prevalence
of hypertension between the two groups of
relatives in Study IV. The latter fact was some-
what surprising, since there was an excess of
familial hypertension in the whole study
population, as demonstrated in Study II. A
recent study has concluded that common ge-
netic determinants of UAER and blood pres-
sure exist in families with type 2 diabetes
[232]. Therefore, the absence of a difference
in blood pressure level in Studies IV and V
may have contributed to the lack of differ-
ence in UAER. However, it should be noted
that all [126, 128, 130] but one [129] of the
four studies in type 2 diabetes found no dif-
ference in blood pressure between relatives of
patients with and without nephropathy de-
spite the difference observed in UAER.
Exercise increases albuminuria in both dia-
betic and non-diabetic subjects [233, 234],
but more pronouncedly in diabetic patients
with early signs of diabetic nephropathy
[233]. Furthermore, a prominent rise in ex-
ercise-induced UAER has been predictive of
subsequent microalbuminuria [235]. The
study by Strojek et al [129] found an exag-
gerated albuminuric response to physical ex-
ercise in relatives of albuminuric compared
to normoalbuminuric type 2 diabetic patients,
a 16-fold vs a 6-fold increase, respectively
[129]. No such tendency was evident in Study
V, which further supports the theory of dif-
ferences in mode of inheritance of UAER be-
tween type 1 and type 2 diabetes.
How can such a difference between type 1
and type 2 diabetes be explained? One possi-
bility may be that a common familial sus-
ceptibility to elevated UAER exists in both
types of diabetes, but that an additional trig-
ger, such as diabetes, dyslipidemia, or hyper-
tension, is needed for the susceptibility to
manifest itself as increased UAER. Non-dia-
betic individuals with a family history of type
2 diabetes display various metabolic and he-
modynamic alterations [144, 145] not
present in non-diabetic subjects with a fam-
ily history of type 1 diabetes [236]. It may
be hypothesized that such an unmasking trig-
ger is present in the non-diabetic relatives of
type 2 diabetic patients, but not in those of
type 1 diabetic patients. It is therefore of in-
terest that in Study IV, hypertensive relatives
had higher UAER than normotensive rela-
tives when it was specifically assessed in the
relatives of patients with nephropathy. No
such effect appeared among relatives of pa-
tients without nephropathy. The comparison
was, however, made between small groups
and does not allow any further conclusions
to be drawn, but if the albuminuric response
to hypertension indeed differs between rela-
tives of patients with and without nephropa-
thy, it would favor this hypothesis. Moreover,
the finding that persistently elevated UAER
is often present at diagnosis [237] and even
precedes development of type 2 diabetes
[238] but is usually absent at diagnosis of
type 1 diabetes [239] is compatible with this
hypothesis.
On the other hand, the discrepancy may
also reflect differences in susceptibility to el-
evated UAER between type 1 and type 2 dia-
betes. In support of this, only 30% of type 2
diabetic patients with microalbuminuria
(comparable to the cases included in the stud-
ies in type 2 diabetes [126, 128–130]) have
been found to have structural lesions typical
of diabetic nephropathy [240]. Type 1 dia-
betic patients with overt proteinuria (compa-
rable to our cases) have the morphologically
rather monotonous pattern typical of diabetic
nephropathy [59]. Microalbuminuria is, fur-
thermore, a strong predictor of overt diabetic
nephropathy in type 1 diabetes [20–22], while
in type 2 diabetes, microalbuminuria is, in-
stead, prognostic of cardiovascular events
[241]. Therefore, differences regarding
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mechanisms behind elevated UAER, and per-
haps also in genetic susceptibility to albumin-
uria, may exist between type 1 and type 2
diabetes.
Familial clustering – genes or
environment?
The basis for genetic susceptibility to diabetic
nephropathy is mostly based upon evidence
of familial clustering, not only of diabetic
nephropathy [6, 120–123], but also of traits
clustering in the family members of patients
with nephropathy, as in the present studies.
However, familial clustering can be demon-
strated for almost any disease [242], and it is
difficult to differentiate to what extent this is
due to shared genes on the one hand and to
similar known and unknown environmental
factors on the other. A simulation study has
provided some insight into this problem
[243]. By assuming no genetic susceptibility
at all, it found that familial clustering of en-
vironmental factors with a relative risk for
disease of less than 10 lead to only a minor
increase in familial clustering of disease, even
in the case of complete correlation of expo-
sure. Therefore, genetic factors, acting either
on their own or in concert with the environ-
ment, ought to be important in the familial
clustering of a disease. This view is supported
by recent segregation analyses in type 2 dia-
betes [154, 155].
During the last decade, many attempts
have been made to identify one or several
genes that increase susceptibility to diabetic
nephropathy, but thus far, no gene has been
identified with any major impact on the de-
velopment of nephropathy [156]. What are
the implications of the present studies in the
search for diabetic nephropathy susceptibil-
ity genes? First, the association of diabetic
nephropathy with familial hypertension is
confirmed (Study I). If identified, genes asso-
ciated with hypertension of early onset are of
particular interest. Second, genes related to
diabetes, to the metabolic syndrome, or espe-
cially to impaired insulin secretion qualify as
candidate genes for diabetic nephropathy
(Studies II and III). Finally, and most impor-
tantly, differences may exist between suscep-
tibility to elevated UAER in type 1 and type
2 diabetes (Studies IV and V). Distinct
subphenotyping of the type of diabetes in the
patients studied may therefore prove worth-
while, and results from studies with mixed
type 1 and type 2 diabetic patients should be
interpreted with caution.
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1. Diabetic nephropathy was associated with
a familial predisposition to hypertension.
Genetic or environmental factors related
to hypertension, especially to a more se-
vere form of hypertension manifested rela-
tively early in life, may be important in
the development of diabetic nephropathy
in type 1 diabetes.
2. Diabetic nephropathy was associated with
a familial predisposition to diabetes. Fac-
tors related to familial clustering of dia-
betes may predispose to diabetic nephr-
opathy in type 1 diabetes.
3. In relatives of patients with diabetic neph-
ropathy, diminished insulin secretion
Summary and conclusions
rather than impaired insulin sensitivity,
characterized early abnormalities in glu-
cose metabolism. This may explain the
excess of diabetes found in relatives of pa-
tients with nephropathy. In the develop-
ment of diabetic nephropathy, factors re-
lated to impaired insulin secretion need
to be further evaluated.
4. No abnormalities of UAER were present
in non-diabetic first-degree relatives of type
1 diabetic patients with diabetic nephropa-
thy. This differs from what has been found
in type 2 diabetes and may suggest differ-
ences in susceptibility to albuminuria be-
tween type 1 and type 2 diabetes.
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